Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C. Visseren-Grul

P3.01-75 RELAY+, an Exploratory Study of Gefitinib With Ramucirumab in Untreated Patients With EGFR Mutation-Positive Metastatic NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.13-30 Neutrophil-To-Lymphocyte Ratio as a Prognostic Factor and Its Relationship to NSCLC Patient Outcomes in the REVEL Trial

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Related publications

MA26.10 CNS Activity of Ramucirumab in Combination With Osimertinib in Patients With Advanced T790m-Positive EGFR-Mutant NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-33 EGFR Mutation in Patients With NSCLC and Its Relationship Between Survival and Clinicopathological Features: An Update Analysis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Osimertinib With Ramucirumab in EGFR Mutated, T790m-Positive Patients Who Had Progressed EGFR-TKIs: Phase Ib Study

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2018English

P3.01-85 Real-World Gefitinib 1st Line Treatment of Patients With Advanced NSCLC and EGFR Mutations - Serbian Single Center Experience

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients With NSCLC Harboring EGFR Mutations.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA03 Afatinib Followed by Osimertinib in Real-World Patients With EGFR Mutation-Positive Advanced NSCLC: The Giotag Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Phase I Study of Vorinostat With Gefitinib in BIM Deletion Polymorphism/Egfr Mutation Double‐positive Lung Cancer

Cancer Science
Cancer ResearchMedicineOncology
2020English

Effects of Antacids on Clinical Efficacy of Gefitinib in Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
2017English

OA10.01 Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy